ECT efficacious, cost-effective for individuals with treatment-resistant major depression
MedPage Today reported that an analysis suggests electroconvulsive therapy (ECT) is efficacious and also cost-effective for patients with treatment-resistant major depression, and it should be considered after failure of two prior trials of pharma-cotherapy and/or psychotherapy.
When investigators constructed a decision analytic model to simulate the clinical and economic
impact of ECT in patients who had not responded to drugs or psychotherapy, they found the treatment to be associated with improved clinical outcomes and a reduction in time having uncontrolled depression. Their analysis suggests that offering ECT after failure of two lines of pharmacotherapy and/or psychotherapy would most reliably maximize ECT’s health-economic value.
The findings were published online in JAMA Psychiatry.